Drug development pipeline

Lead Program: 4MT2001

4MT2001 is the primary metabolite of ruboxistaurin, a drug developed by Eli Lilly with established safety data in over 2,000 patients. 4M Therapeutics discovered that both ruboxistaurin and 4MT2001 inhibit GSK3β. 4MT2001 combines the de-risked clinical safety of ruboxistaurin with improved GSK3β potency and selectivity, a superior pharmacokinetic and pharmacodynamic profile, and the potential for once daily dosing. Safety and efficacy data to date for 4MT2001 support its potential as a best-in-class treatment for bipolar disorder – a condition affecting 7 million people in the U.S. alone.

4MT-01 Series

Our 4MT-01 series includes some of the most potent and specific GSK3β inhibitors ever developed. We are developing the series initially for the treatment of agitation in Alzheimer’s disease, where lithium has shown potential, yet substantial unmet clinical need remains.

4MT-04 Series

The 4MT-04 series, a peptide inhibitor of the hyperactivated CDK5/p25 complex, is supported by groundbreaking research from our scientific founders. 4MT04 demonstrated efficacy in rescuing learning and memory deficits and reducing microgliosis and neuronal loss in an aged animal model of tau pathology. It may provide breakthrough potential in neurodegenerative diseases.